FDA — authorised 29 August 2017
- Application: NDA209776
- Marketing authorisation holder: REMPEX
- Local brand name: VABOMERE
- Indication: POWDER — INTRAVENOUS
- Status: approved
🇺🇸 Meropenem-Vaborbactam in United States
FDA authorised Meropenem-Vaborbactam on 29 August 2017
Marketing authorisation
Other Infectious Disease approved in United States
Frequently asked questions
Is Meropenem-Vaborbactam approved in United States?
Yes. FDA authorised it on 29 August 2017.
Who is the marketing authorisation holder for Meropenem-Vaborbactam in United States?
REMPEX holds the US marketing authorisation.